CorMedix Therapeutics reported Q3 revenue of $54.5M (above $51.2M consensus), net loss of $14.7M, and adjusted EBITDA of $3.1M. The company maintained FY2026 revenue guidance of $325-345M and narrowed adjusted EBITDA guidance to $130-140M. It suspended 2027 DefenCath revenue guidance due to CMS reimbursement changes. The pending Heron Therapeutics acquisition and REZZAYO sNDA review remain key catalysts.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
